1627 - Retrospective analysis of cancer and chemotherapy induced anaemia treated with ferric carboxymaltose only, an intravenous iron therapy

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Supportive Care
Presenter Barbara Tschechne
Authors B. Tschechne1, S. Broszeit-Luft2, O. Harlin3, W.O. Jordan2, H. Zakaria4
  • 1Haematologisch-onkologische Praxis Neustadt, 31535 - Neustadt a. Rbge./DE
  • 2-, Haematologisch-onkologische Praxis Lehrte, 31275 - Lehrte/DE
  • 3-, Vifor Pharma Deutschland GmbH, 81379 - München/DE
  • 4NewConceptOncology GmbH, 31275 - Lehrte/DE


Chemotherapy induced anaemia is often treated with ESAs and/or blood transfusions. Oral or intravenous iron substitution represent alternatives for both cancer and chemotherapy induced anaemia. Current discussions focus on intravenous treatment to increase Hb levels in cancer patients, as oral treatments are often associated with limited response rates and gastrointestinal side effects. This retrospective, single centre analysis investigates the effectiveness of an iv iron compound, ferric carboxymaltose (Ferinject® [FCM]) as the only anaemia treatment in an unselected, routinely treated anaemic cancer patient population between 2009 and 2012. Patients fulfilling the following criteria were included in the analysis: malignant cancer diagnosis, anaemia, FCM treatment ≧ 4 weeks, complete available documentation ≧ 12 weeks, no ESA or other iron medication and no blood transfusion during the observation period. At baseline, sex, age, tumour history, anti-tumour treatment and history of anaemia treatment during the four weeks prior the retrospective analysis were recorded. Modalities of FCM treatment and serum levels of available relevant laboratory parameters (e.g. Hb, transferrin saturation [TSAT], ferritin, haematocrit) were recorded at baseline and throughout the observation period. Treatment response, tolerability and adverse reactions for a total of 59 cancer patients were investigated. The median age was 61 (20-91) years, of these 14 were male and 45 female. During the FCM therapy, 52 patients were not treated actively for cancer and 7 patients were on anticancer treatment. Median Hb increase was 2.0 g/dl compared to baseline (range: 0 to 6.2 g/dl). Patients received on average 336 mg iron (range: 100-1700mg). No adverse events related to FCM were recorded. The results of our retrospective analysis demonstrate the safety and effectiveness of FCM therapy in correction of anaemia in cancer patients prior, during or after completed chemotherapy. More long-term data on FCM exposure in cancer patients with iron deficiency are needed in order to characterize which patients benefit most from this therapy and to determine optimal dosing and frequency of FCM use.


B. Tschechne: I am a member of the Advisory Board of Vifor Pharma Deutschland

O. Harlin: employee of Vifor Pharma Germany

H. Zakaria: The data analysis shown was sponsored by Vifor Pharma Deutschland

All other authors have declared no conflicts of interest.